Tengion (TNGNQ) 10-Q 14 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 07, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'TENGION INC	'
Entity Central Index Key	'0001296391	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	25,049,607
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'

Balance_Sheets_unaudited

Balance Sheets (unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$10,124	$21,510
Prepaid expenses and other	485	334
Total current assets	10,609	21,844
Property and equipment, net of accumulated depreciation of $13,339 and $13,441 as of December 31, 2013 and June 30, 2014, respectively	511	454
Other assets	3,077	3,426
Total assets	14,197	25,724
Current liabilities:	'	'
Current portion of long-term debt, net of debt discount of $52 December 31, 2013	0	1,329
Current portion of lease liability	675	665
Accounts payable	661	853
Accrued expenses	1,807	2,366
Warrant liability	47,000	11,425
Total current liabilities	50,143	16,638
Long-term debt and embedded derivative, net of debt discount of $7,814 and $5,581 as of December 31, 2013 and June 30, 2014, respectively	29,727	25,623
Lease liability	183	307
Other liabilities	12	12
Total liabilities	80,065	42,580
Commitments and contingencies (Note 13)	'	'
Stockholders' deficit:	'	'
Preferred stock, $0.001 par value; 10,000 shares authorized; zero shares issued or outstanding at December 31, 2013 and June 30, 2014	0	0
Common stock, $0.001 par value; 750,000 shares and 10,000,000 shares authorized at December 31, 2013 and June 30, 2014, respectively; 6,822 and 21,847 shares issued and outstanding at December 31, 2013 and June 30, 2014, respectively	22	7
Additional paid-in capital	252,323	249,237
Accumulated deficit	-318,213	-266,100
Total stockholders' deficit	-65,868	-16,856
Total liabilities and stockholders' deficit	$14,197	$25,724

Balance_Sheets_unaudited_Paren

Balance Sheets (unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Accumulated depreciation, property and equipment	$13,441	$13,339
Current liabilities:	'	'
Current portion of long-term debt, debt discount	'	52
Long-term debt, debt discount	$5,581	$7,814
Stockholders equity:	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	10,000,000,000	750,000,000
Common stock, shares issued (in shares)	21,847,000	6,822,000
Common stock, shares outstanding (in shares)	21,847,000	6,822,000

Statements_of_Operations_and_C

Statements of Operations and Comprehensive Loss (unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statements of Operations and Comprehensive Loss (unaudited) [Abstract]	'	'	'	'
Revenue	$0	$0	$0	$0
Operating expenses:	'	'	'	'
Research and development	2,766	2,480	5,250	4,660
General and administrative	1,839	1,445	3,562	3,295
Depreciation	53	62	102	145
Other expense, net	151	91	304	121
Total operating expenses	4,809	4,078	9,218	8,221
Loss from operations	-4,809	-4,078	-9,218	-8,221
Interest income	5	2	14	7
Interest expense	-1,881	-1,830	-3,845	-3,257
Change in fair value of embedded derivative and derivative liability	-114	-4,104	-3,775	-4,438
Change in fair value of warrant liability	-11,056	-1,925	-35,289	-1,800
Net loss	-17,855	-11,935	-52,113	-17,709
Other comprehensive loss	0	0	0	0
Comprehensive loss	($17,855)	($11,935)	($52,113)	($17,709)
Basic and diluted net loss per share (in dollars per share)	($0.82)	($3.59)	($2.62)	($5.84)
Weighted-average common stock outstanding - basic and diluted (in shares)	21,772	3,325	19,871	3,034

Statements_of_Stockholders_Def

Statements of Stockholders' Deficit (unaudited) (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2013	$7	$249,237	($266,100)	($16,856)
Balance (in shares) at Dec. 31, 2013	6,822,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Issuance of common stock for payment of interest	6	1,347	0	1,353
Issuance of common stock for payment of interest (in shares)	6,293,000	'	'	'
Cancellation of restricted stock to employees	0	-1	0	-1
Cancellation of restricted stock to employees (in shares)	-4,000	'	'	'
Issuance of common stock to convertible noteholders	9	1,490	0	1,499
Issuance of common stock to convertible noteholders (in shares)	8,736,000	'	'	'
Stock-based compensation expense	0	250	0	250
Net loss	0	0	-52,113	-52,113
Balance at Jun. 30, 2014	$22	$252,323	($318,213)	($65,868)
Balance (in shares) at Jun. 30, 2014	21,847,000	'	'	'

Statements_of_Cash_Flows_unaud

Statements of Cash Flows (unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($52,113)	($17,709)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	102	145
Change in fair value of embedded derivative and derivative liability	3,775	4,438
Change in fair value of warrant liability	35,289	1,800
Charge related to lease liability	304	231
Noncash interest expense	3,807	2,312
Noncash rent expense	0	2
Stock-based compensation expense	250	276
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other assets	-151	-127
Accounts payable	-189	1,313
Accrued expenses and other	-914	-383
Net cash used in operating activities	-9,840	-7,702
Cash flows from investing activities:	'	'
Change in restricted cash	0	1,000
Cash paid for property and equipment	-163	-2
Net cash provided by (used in) investing activities	-163	998
Cash flows from financing activities:	'	'
Proceeds from sales of common stock and warrants, net	-1	195
Proceeds from long-term debt and warrants, net of issuance costs	0	12,846
Payments on long-term debt	-1,382	0
Net cash provided by (used in) financing activities	-1,383	13,041
Net (decrease) increase in cash and cash equivalents	-11,386	6,337
Cash and cash equivalents, beginning of period	21,510	7,536
Cash and cash equivalents, end of period	$10,124	$13,873

Organization_and_Nature_of_Ope

Organization and Nature of Operations	6 Months Ended
	Jun. 30, 2014
Organization and Nature of Operations [Abstract]	'
Organization and Nature of Operations	'
	-1	Organization and Nature of Operations
	Tengion, Inc. (the Company) was incorporated in Delaware on July 10, 2003.  The Company is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  Using its Organ Regeneration Platform, the Company creates these neo-organs using a patient’s own cells, or autologous cells.  The Company’s mission is to: (i) utilize its Organ Regeneration Platform to extend the lives of patients suffering from life-threatening diseases; (ii) improve the quality of patients' lives while providing cost-saving treatments; and (iii) create value for the Company’s stakeholders.
	The Company believes its proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues.  The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.  In addition, the Company’s neo-organs are designed to replace the need to substitute other tissues of the body for a purpose to which they are poorly suited.
	Building on its clinical and preclinical experience, the Company has utilized its Organ Regeneration Platform in the conduct of its Neo-Kidney Augment development program for patients with advanced chronic kidney disease and its Neo-Urinary Conduit development program for bladder cancer patients who are in need of a urinary diversion.  The Company operates as a single business segment.  Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product candidate development; technological uncertainty; dependence on collaborative partners; uncertainty regarding patents and proprietary rights; comprehensive government regulations; having no commercial manufacturing experience, marketing or sales capability or experience; and dependence on key personnel.

Managements_Plans_to_Continue_

Management's Plans to Continue as a Going Concern	6 Months Ended
	Jun. 30, 2014
Management's Plans to Continue as a Going Concern [Abstract]	'
Management's Plans to Continue as a Going Concern	'
	-2	Management’s Plans to Continue as a Going Concern
	The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  The Company has incurred losses since inception and has an accumulated deficit of $318.2 million as of June 30, 2014, including $48.4 million of cumulative accretion of redeemable convertible preferred stock through the date of its conversion to common stock in April 2010.  The Company anticipates incurring additional losses and deficits in operating cash flows until such time, if ever, that it can generate significant sales of its therapeutic product candidates currently in development or enters into cash flow positive business development transactions.
	Based upon the Company’s current expected level of operating expenditures and required debt repayments, and assuming the Company is not required to settle any outstanding warrants in cash or redeem, or pay cash interest on, any of its convertible notes, the Company expects to be able to fund operations through December 31, 2014; however, this period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events.  The Company plans to raise additional funds through collaborative arrangements, public or private sales of debt or equity securities, commercial loan facilities, or some combination thereof.  There is no assurance that additional financing will be available when needed to allow the Company to continue its operations or if available, on terms acceptable to the Company.
	In the event financing is not obtained, the Company could pursue additional headcount reductions and other cost cutting measures to preserve cash as well as explore the sale of selected assets to generate additional funds.  If the Company is required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs, these events could have a material adverse effect on the Company's business, results of operations and financial condition.
	These factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Summary_of_Accounting_Policies

Summary of Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Accounting Policies [Abstract]	'
Summary of Accounting Policies	'
	-3	Summary of Accounting Policies
	Use of Estimates
	The preparation of financial statements, in accordance with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.  Actual results could differ from those estimates.  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
	Recently Adopted Accounting Standards
	In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) – Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (ASU 2014-10).  ASU 2014-10 eliminates the concept of a development stage entity in its entirety from current accounting guidance. The new guidance eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of operations, stockholders’ equity and cash flows, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.  ASU 2014-10 is effective prospectively for public entities for annual reporting periods beginning after December 15, 2015, and interim periods within those annual periods however early adoption is permitted.  The Company evaluated and elected to adopt ASU 2014-10 as permitted, and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities in these financial statements.
	Net Loss Per Share
	Basic and diluted net loss attributable to common stockholders per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. For all periods presented, the outstanding shares of unvested restricted stock as well as the number of common shares issuable upon exercise of outstanding stock options and warrants and conversion of notes payable have been excluded from the calculation of diluted net loss attributable to common stockholders per share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and dilutive loss per share are the same.
	The following potentially dilutive securities have been excluded from the three and six month computations of diluted weighted-average shares outstanding as they would be anti-dilutive:
			June 30,
			2013		2014
	Shares underlying warrants outstanding			187,718,221		665,421,057
	Shares underlying options outstanding			232,046		229,957
	Unvested restricted stock			54,939		35,574
	Convertible notes payable			48,668,482		149,082,064
	The Company has determined that the net loss per share - basic and diluted for the three-month period ended March 31, 2014 was incorrectly stated in the Form 10-Q for the period ended March 31, 2014, resulting from an error in the calculation of weighted-average basic shares outstanding for the three-month period ended March 31, 2014. The Company determined that the error is not material to the March 31, 2014 financial statements. The net loss per share - basic and diluted for the three-month period ended March 31, 2014 was previously reported as $(1.91), while the corrected amount is $(2.55).

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2014
Supplemental Cash Flow Information [Abstract]	'
Supplemental Cash Flow Information	'
	-4	Supplemental Cash Flow Information
	The following table contains additional supplemental cash flow information for the periods reported (in thousands).
			Six months ended
			June 30,
			2013		2014
	Supplemental disclosure of non-cash transactions:
	Fair value of embedded derivatives and derivatives issued with issuance of long-term debt		$	732	$	—
	Fair value of warrants issued with issuance of long-term debt			9,657		—
	Fair value of warrants issued pursuant to Celgene Collaboration and Option Agreement			3,390		—
	Conversion of warrant liability to common stock			15		—
	Conversion of 2012 and 2013 Convertible Notes to common stock, net			-		1,499
	Issuance of common stock and warrants for payment of interest			749		1,639

Financial_Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2014
Financial Instruments [Abstract]	'
Financial Instruments	'
	-5	Financial Instruments
	The fair value guidance requires fair value measurements be classified and disclosed in one of the following three categories:
		·	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
		·	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
		·	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liability measured at fair value on a recurring basis as of December 31, 2013 and June 30, 2014 (in thousands).
			Fair value measurement at reporting date using:
			Quoted prices in active markets for identical assets (Level 1)		Significant other observable		Significant unobservable inputs		Total
					inputs		(Level 3)
					(Level 2)
	At December 31, 2013
	Assets:
	Cash and cash equivalents		$	21,510	$	—	$	—	$	21,510
	Liabilities:
	Embedded derivative liability		$	—	$	—	$	226	$	226
	Warrant liability			—		—		11,425		11,425
			$	—	$	—	$	11,651	$	11,651
	At June 30, 2014:
	Assets:
	Cash and cash equivalents		$	10,124	$	—	$	—	$	10,124
	Liabilities:
	Embedded derivative liability		$	—	$	—	$	4,001	$	4,001
	Warrant liability			—		—		47,000		47,000
			$	—	$	—	$	51,001	$	51,001
	The Company issued notes in 2012 and 2013 that are convertible into common stock at the option of the holder (collectively, the Conversion Options).  See Note 10 for further discussion of these Conversion Options, which are accounted for as embedded derivative liabilities. These Conversion Options are measured at fair value on a recurring basis using unobservable inputs and available market data to support the fair value (Level 3).  A reconciliation of the embedded derivative liabilities is as follows (in thousands):
			2012 Notes		2013 Notes		Total
	Balance at December 31, 2013		$	101	$	125	$	226
	Change in fair value of derivative liability			1,687		2,088		3,775
	Balance at June 30, 2014		$	1,788	$	2,213	$	4,001
	The Company has issued warrants to purchase common stock that are measured at fair value on a recurring basis using unobservable inputs and available market data to support the fair value (Level 3).  See Note 11 for further discussion of the warrant liability.  A reconciliation of the warrant liability is as follows (in thousands):
			2011		2012		2013		2013		2013 and			Total
			Warrants		Warrants		Warrants		Celgene Warrants		2014
											Interest Warrants
	Balance at December 31, 2013		$	720	$	3,430	$	5,139	$	2,083	$	53		$	11,425
	Issuance of warrants			—		—		—		—		286			286
	Change in fair value of warrant liability			3,748		10,409		15,060		6,108		(36	)		35,289
	Balance at June 30, 2014		$	4,468	$	13,839	$	20,199	$	8,191	$	303		$	47,000
	The fair value of the Conversion Options, 2011 Warrants, 2012 Warrants, 2013 Warrants, 2013 Celgene Warrants, and 2013 and 2014 Interest Warrants as of December 31, 2013 and June 30, 2014, was determined using a risk-neutral framework within a Monte Carlo analysis. The valuation of the Conversion Options and Warrants is subjective and is affected by changes in inputs to the valuation model including the assumptions regarding the aggregate value of the Company’s debt and equity instruments; assumptions regarding the expected amounts and dates of future debt and equity financing activities; assumptions regarding the likelihood and timing of Fundamental Transactions or Major Transactions (as defined in the agreements); the historical and prospective volatility in the value of the company’s debt and equity instruments; risk-free rates based on U.S. Treasury security yields; and the Company’s dividend yield.
	In performing the valuation of the Conversion Options, 2011 Warrants, 2012 Warrants, 2013 Warrants, 2013 Celgene Warrants, and 2013 and 2014 Interest Warrants, the Company believed the common stock price has not fully adjusted for the potential future dilution from the private placement transactions in 2012 and 2013.  Therefore, the Company used an implied enterprise value considering potential future values for the Company contingent on the outcome of its research programs in conjunction with a Monte Carlo analysis to estimate the range of possible outcomes within each scenario and to allocate value to the securities in accordance with the terms of the agreements. The valuation resulted in a model-derived common stock value of $0.02 per share and $0.08 per share as of December 31, 2013 and June 30, 2014, respectively, primarily due to the preference rights of the debt holders and the anti-dilution and net cash settlement features of warrants issued in 2011, 2012 and 2013. Changes in these assumptions can materially affect the fair value estimate.
	Certain assets and liabilities, including property and equipment, severance benefits and the lease liability, are measured at fair value on a nonrecurring basis.  These assets and liabilities are recognized at fair value when they are deemed to be impaired or in the period in which the liability is incurred.  None of these assets were measured at fair value as of December 31, 2013 or June 30, 2014.

Accrued_expenses

Accrued expenses	6 Months Ended
	Jun. 30, 2014
Accrued expenses [Abstract]	'
Accrued expenses	'
	-6	Accrued expenses
	Accrued expenses consist of the following (in thousands):
			December 31,		June 30,
			2013		2014
	Accrued interest on convertible notes		$	843	$	781
	Accrued compensation and benefits			757		460
	Accrued consulting and professional fees			138		275
	Accrued research and development			535		199
	Other			93		92
	Total accrued expenses		$	2,366	$	1,807

Lease_liability

Lease liability	6 Months Ended
	Jun. 30, 2014
Lease liability [Abstract]	'
Lease liability	'
	-7	Lease liability
	The Company entered into an agreement in February 2006 to lease warehouse space from March 1, 2011 through February 28, 2016.  On March 1, 2011, the Company determined it was not likely to utilize the space during the five-year lease term.  Therefore, the Company recorded a liability as of March 1, 2011, the cease-use date, for the fair value of its obligations under the lease.  The most significant assumptions used in determining the amount of the estimated lease liability are the potential sublease revenues and the credit-adjusted risk-free rate utilized to discount the estimated future cash flows.
	In connection with the 2011 restructuring, the Company determined it was not likely to utilize substantially all of the leased office and manufacturing space in its East Norriton, Pennsylvania facility during the remainder of the lease term or February 28, 2016.  Therefore, the Company recorded a liability as of November 30, 2011, the cease-use date, for the fair value of its obligations under the lease.
	The following table summarizes the activity related to the lease liability for the six month period ended June 30, 2014 (in thousands).
			Warehouse			Office and manufacturing			Total
			space			space
	Balance at December 31, 2013		$	500		$	472		$	972
	Charges utilized			(128	)		(290	)		(418	)
	Additional charges to operations			27			277			304
	Balance at June 30, 2014			399			459			858
	Less current portion			246			429			675
	Total long-term lease liability at June 30, 2014		$	153		$	30		$	183

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt [Abstract]	'
Debt	'
	-8	Debt
	Senior Secured Convertible Notes
	2013 Financing
	On June 28, 2013, the Company completed a private placement (the 2013 Financing) of an aggregate principal amount of $18,576,000 of Senior Secured Convertible Notes (the 2013 Convertible Notes) along with warrants to the holders of the Convertible Notes (2013 Warrants) to purchase 26,921,741 shares of our common stock exercisable for a period of five years from the date of their issuance and warrants to purchase 53,843,479 shares of our common stock exercisable for a period of ten years from the date of their issuance. The initial conversion price of the 2013 Convertible Notes was $0.69 per share and the initial exercise price of the 2013 Warrants was $0.69 per share. The 2013 Convertible Notes mature on June 30, 2016 and bear interest at 10% per annum, which is payable quarterly beginning on October 1, 2013. The 2013 Convertible Notes were initially convertible into 26,921,740 shares of common stock at a conversion price of $0.69 per share. The Company recorded an embedded derivative liability for the Conversion Option (the Conversion Option-2013 Notes). The Conversion Option-2013 Notes is presented on the Balance Sheet, included with long-term debt. See Note 10 for further discussion of this embedded derivative liability.
	We may, at our option, pay interest by the issuance of common stock (or, in certain circumstances, warrants to purchase shares of common stock), provided that an event of default has not occurred and we have publicly disclosed all material information about the Company. If we elect to pay interest on the 2013 Convertible Notes through the issuance of shares of our common stock, the number of shares that would be issued is calculated by dividing the amount of the interest payment by the lesser of: (1) the volume weighted-average price (VWAP) for our common stock for the twenty trading days prior to the date the interest payment is due or (2) the closing bid price for our common stock as of the last trading day of the VWAP period. All shares of common stock issuable to the holders in lieu of interest payments will be allocated pro rata among the holders based on the outstanding principal amount of the 2013 Convertible Notes.
	On January 2, 2014 and April 1, 2014, we made interest payments to the holders of the 2012 Convertible Notes (as defined below) and the 2013 Convertible Notes by the issuance of shares of common stock and warrants to purchase shares of common stock for nominal consideration. Both the January 2, 2014 and April 1, 2014 issuances of the shares and warrants were dilutive to the holders of the 2013 Warrants, 2013 Celgene Warrants, 2013 Convertible Notes, 2012 Warrants, 2012 Convertible Notes, and 2011 Warrants, and the anti-dilution provisions of each were simultaneously triggered. As of June 30, 2014, the conversion price of the 2013 Convertible Notes was adjusted to $0.21 per share and the number of shares issuable upon exercise of the 2013 Convertible Notes was increased to 80,009,439 shares.
	2012 Financing
	On October 2, 2012, the Company completed a private placement of an aggregate principal amount of $15,005,251 of Senior Secured Convertible Notes (the 2012 Convertible Notes) along with warrants to the holders of the Convertible Notes (2012 Warrants) to purchase 1,118,722 shares of our common stock exercisable for a period of two years from the date of their issuance, warrants to purchase 16,672,145 shares of our common stock exercisable for a period of five years from the date of their issuance and warrants to purchase 33,344,293 shares of our common stock exercisable for a period of ten years from the date of their issuance at an initial exercise price of $0.75 per share. The 2012 Convertible Notes mature on October 2, 2015 and bear interest at 10% per annum. The Company recorded an embedded derivative liability for the Conversion Option (the Conversion Option-2012 Notes). The Conversion Option-2012 Notes is presented on the Balance Sheet, included with long-term debt. See Note 10 for further discussion of this embedded derivative liability.
	On January 2, 2014 and April 1, 2014, we made interest payments to the holders of the 2012 Convertible Notes and the 2013 Convertible Notes by the issuance of shares of common stock and warrants to purchase shares of common stock for nominal consideration. Both the January 2, 2014 and April 1, 2014 issuances of the shares and warrants were dilutive to the holders of the 2013 Warrants, 2013 Convertible Notes, 2013 Celgene Warrants, 2012 Warrants, 2012 Convertible Notes, and 2011 Warrants, and the anti-dilution provisions of each were simultaneously triggered. As of June 30, 2014, the conversion price of the 2012 Convertible Notes was adjusted to $0.21 per share and the number of shares issuable upon exercise of the 2012 Convertible Notes was increased to 69,072,625 shares.
	Total debt outstanding consists of the following (in thousands):
			December 31,			June 30,
			2013			2014
	Senior Secured 2012 Convertible Notes		$	14,634		$	14,505
	Embedded derivative liability-2012 Notes			101			1,788
	Senior Secured 2013 Convertible Notes			18,576			16,802
	Embedded derivative liability-2013 Notes			125			2,213
	Working Capital Note			1,382			—
	Unamortized debt discount			(7,866	)		(5,581	)
				26,952			29,727
	Less current portion			(1,329	)		—
	Total long-term debt and embedded derivative, net of debt discount		$	25,623		$	29,727
	The Company recorded interest expense of $1.8 million and $1.9 million for the three months ended June 30, 2013 and 2014, respectively. Included in interest expense for the three months ended June 30, 2014 is $0.4 million of amortization of deferred financing costs and debt discount related to the 2013 Convertible Notes, $0.7 million in amortization of deferred financing costs and debt discount on the 2012 Convertible Notes and Working Capital Note and $0.8 million of interest expense on the 2012 Convertible Notes, Working Capital Note and 2013 Convertible Notes. The Company recorded interest expense of $3.3 million and $3.8 million for the six months ended June 30, 2013 and 2014, respectively. Included in interest expense for the six months ended June 30, 2014 is $0.7 million of amortization of deferred financing costs and debt discount related to the 2013 Convertible Notes, $1.5 million in amortization of deferred financing costs and debt discount on the 2012 Convertible Notes and Working Capital Note and $1.6 million of interest expense on the 2012 Convertible Notes, Working Capital Note and 2013 Convertible Notes.
	During 2014, approximately $0.1 million of the 2012 Convertible Notes were converted into 638,480 shares of our common stock and approximately $1.8 million of the 2013 Convertible Notes were converted into 8,097,256 shares of our common stock.
	During 2014, the Company had issued 6,292,552 Interest Shares and 1,298,904 Interest Warrants to satisfy approximately $1.6 million in interest obligations for the 2012 Convertible Notes and 2013 Convertible Notes.

Capital_Structure

Capital Structure	6 Months Ended
	Jun. 30, 2014
Capital Structure [Abstract]	'
Capital Structure	'
	-9	Capital Structure
	Common Stock
	Since inception, the Company has sold common stock to certain officers, directors, employees, consultants, Scientific Advisory Board members and investors.  As of June 30, 2014, the Company was authorized to issue 10,000,000,000 shares of common stock.  Each holder of common stock is entitled to one vote for each share held.  The Company will, at all times, reserve and keep available out of its authorized but unissued shares of common stock sufficient shares to effect the exercise of outstanding stock options and warrants.
	Preferred Stock
	The Company was authorized to issue 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof.  These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.  The issuance of the Company’s preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.  In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control of the Company or other corporate action.  There are no shares issued or outstanding as of June 30, 2014.
	Registration Rights Agreements
	In connection with the 2013 Financing and the Celgene Collaboration and Option Agreement, we entered into a Registration Rights Agreement (the 2013 Registration Rights Agreement) with the 2013 investors and Celgene. The 2013 Registration Rights Agreement provided that, within 30 days of the closing of the 2013 Financing, we would file a “resale” registration statement (the Registration Statement) covering up to the maximum number of shares underlying the 2013 Notes, 2013 Warrants and the Celgene Warrants that we were able to register pursuant to applicable Securities and Exchange Commission (SEC) limitations. We filed the Registration Statement on July 26, 2013 and it was declared effective by the SEC on September 18, 2013. Under the terms of the 2013 Registration Rights Agreement, we are obligated to maintain the effectiveness of the Registration Statement until all securities therein are sold or otherwise can be sold without registration and without any restrictions.
	In connection with the private placement we completed in October 2012 (the 2012 Financing), we entered into a registration rights agreement, which has since been amended, with the investors in the 2012 Financing (as amended, the 2012 Registration Rights Agreement). The 2012 Registration Rights Agreement provided that, within 30 days of the closing of the 2012 Financing, we would file a “resale” registration statement covering up to the maximum number of shares of common stock issuable upon (i) the conversion of the senior secured convertible notes that were issued in the 2012 Financing and (ii) the exercise of the warrants issued in the 2012 Financing. We filed the registration statement on November 5, 2012 and it was declared effective by the SEC on March 28, 2013. Under the terms of the 2012 Registration Rights Agreement, we are obligated to maintain the effectiveness of the registration statements until all securities therein are sold or otherwise can be sold without registration and without any restrictions.

Embedded_Derivative_Conversion

Embedded Derivative Conversion Options	6 Months Ended
	Jun. 30, 2014
Embedded Derivative Conversion Options [Abstract]	'
Embedded Derivative Conversion Options	'
	-10	Embedded Derivative Conversion Options
	The Company accounts for Conversion Options on the 2012 and 2013 Convertible Notes in accordance with Financial Accounting Standards Board Accounting Standard Codification (ASC) 815, Derivatives and Hedging (ASC 815). Under this accounting guidance, the Company is required to bifurcate the embedded derivative from the host instrument and account for it as a derivative financial instrument. These Conversion Options are classified with debt on the balance sheet and remeasured to fair value at each reporting date, with any changes in fair value being recorded on the Statement of Operations and Comprehensive Loss.
	The following table summarizes the calculated aggregate fair values using a risk-neutral framework within a Monte Carlo analysis of the Conversion Options as of the dates indicated along with assumptions utilized in each calculation.
				Embedded Derivative Liability
				Conversion Option-2012						Conversion Option-2013
				Notes						Notes
				31-Dec-13			June 30,			December 31,			June 30,
							2014			2013			2014
			$	101		$	1,788		$	125		$	2,213
	Calculated aggregate value (in thousands)
	Weighted-average equity volatility			120	%		110	%		120	%		110	%
	Weighted-average asset volatility			95	%		85	%		95	%		85	%
	Probability of a Major Transaction			100	%		100	%		100	%		100	%
	Weighted-average risk-free interest rate			0.2	%		0.3	%		0.2	%		0.3	%
	Dividend yield.		None			None			None			None

Warrants

Warrants	6 Months Ended
	Jun. 30, 2014
Warrants [Abstract]	'
Warrants	'
	-11	Warrants
	The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Stock warrants are accounted for as derivative liabilities if the stock warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock are at a lower price per share than the then-current warrant exercise price.  The Company classifies derivative warrant liabilities on the balance sheet as a current liability, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.
	The following table summarizes outstanding warrants to purchase common stock:
			Shares Exercisable as of
			December 31,		June 30,		Weighted-average Exercise
			2013		2014		Price		Expiration
	Equity-classified warrants
	Issued to lenders and vendors		18,375		18,202	$	157.52		September 2014 through
									Sep-19
			18,375		18,202
	Liability-classified warrants
	2013 and 2014 Interest Warrants		1,057,944		2,356,848	$	0.001		July 2023 through April 2024
	2013 Warrants (1)		191,213,801		264,057,161	$	0.21		June 2018 through June 2023
	2013 Celgene Warrants (1)		77,586,207		107,142,857	$	0.21		June 2018 through June 2023
	2012 Warrants (1)		136,663,804		188,726,206	$	0.21		October 2014 through October 2022
	2011 Warrants (2)		74,761,830		103,119,783	$	0.29		Mar-16
			481,283,586		665,402,855
	Total		481,301,961		665,421,057
	(1)As of December 31, 2013 the 2013 Warrants, 2013 Celgene Warrants and 2012 Warrants had an exercise price of $0.29 per share.
	(2)As of December 31, 2013 the 2011 Warrants had an exercise price of $0.40 per share.
	2012 Warrants, 2013 Warrants and 2013 Celgene Warrants
	On October 2, 2012, as part of the 2012 Financing, the Company issued the 2012 Warrants to holders of the 2012 Convertible Notes. The 2012 Warrants were exercisable at an exercise price of $0.75 per share subject to certain adjustments as specified in the warrant agreement. The Company valued the 2012 Warrants as derivative financial instruments as of the date of issuance and will record their changes in fair value at each reporting date, with any changes in fair value being recorded on the Statement of Operations and Comprehensive Loss. On January 2, 2014 and April 1, 2014, the Company made interest payments to the holders of the 2012 Convertible Notes and the 2013 Convertible Notes by the issuance of shares of common stock and warrants to purchase shares of common stock for nominal consideration. Both the January 2, 2014 and April 1, 2014 issuances of the shares and warrants were dilutive to the holders of the 2013 Warrants, 2013 Convertible Notes, 2012 Warrants, 2012 Convertible Notes, and 2011 Warrants, and the anti-dilution provisions of each were simultaneously triggered. As of June 30, 2014, the exercise price of the 2012 Warrants was adjusted to $0.21 per share, and the number of shares issuable upon exercise of the 2012 Warrants was increased to 188,726,206 shares.
	On June 28, 2013, as part of the 2013 Financing, the Company issued the 2013 Warrants to holders of the 2013 Convertible Notes. The 2013 Warrants were initially exercisable at an exercise price of $0.69 per share subject to certain adjustments as specified in the warrant agreement. In addition, on June 28, 2013, the Company entered into a Collaboration and Option Agreement with Celgene Corporation under which Celgene paid the Company $15 million in exchange for (i) five-year warrants to purchase 7,425,743 shares of common stock and ten-year warrants to purchase 14,851,485 shares of common stock (the Celgene Warrants); (ii) a right of first negotiation to the Company’s Neo-Kidney Augment Program; and (iii) entering into the Collaboration and Option Agreement. The Celgene Warrants were initially exercisable at an exercise price of $1.01 per share. The Company valued the 2013 Warrants and the Celgene Warrants as derivative financial instruments as of the date of issuance and will continue to do so at each reporting date, with any changes in fair value being recorded on the Statement of Operations and Comprehensive Loss. On January 2, 2014 and April 1, 2014, the Company made interest payments to the holders of the 2012 Convertible Notes and the 2013 Convertible Notes by the issuance of shares of common stock and warrants to purchase shares of common stock for nominal consideration. Both the January 2, 2014 and April 1, 2014 issuances of the shares and warrants were dilutive to the holders of the 2013 Warrants, 2013 Celgene Warrants, 2013 Convertible Notes, 2012 Warrants, 2012 Convertible Notes, and 2011 Warrants, and the anti-dilution provisions of each were simultaneously triggered. As of June 30, 2014, the exercise price of the 2013 Warrants and 2013 Celgene Warrants was adjusted to $0.21 per share, and the number of shares issuable upon exercise of the 2013 Warrants and 2013 Celgene Warrants was increased to 264,057,161 shares and 107,142,857, respectively.
	The 2012 Warrants, 2013 Warrants and 2013 Celgene Warrants contain provisions that require the modification of the exercise price and shares to be issued under certain circumstances, including in the event the Company completes subsequent equity financings at a price per share lower than the then-current warrant exercise price. In addition, the warrants contain a net cash settlement provision under which the warrant holders may require the Company to purchase the warrants in exchange for a cash payment following the announcement of specified events defined as Major Transactions involving the Company (e.g., merger, sale of all or substantially all assets, tender offer, or share exchange). The net cash settlement provision requires use of the Black-Scholes model in calculating the cash payment value in the event of a Major Transaction.
	2011 Warrants
	In March 2011, the Company issued warrants (2011 Warrants) to purchase 1,046,102 shares of common stock in connection with a private placement transaction. Each warrant was exercisable in whole or in part at any time until March 4, 2016 at a per share exercise price of $28.80, subject to certain adjustments as specified in the warrant agreement. The Company classified the warrants as derivative financial instruments as of the date of issuance (March 4, 2011) and will record the changes in their fair value at each reporting date, with any changes in fair value being recorded on the Statement of Operations and Comprehensive Loss. On January 2, 2014 and April 1, 2014, the Company made interest payments to the holders of the 2012 Convertible Notes and the 2013 Convertible Notes by the issuance of shares of common stock and warrants to purchase shares of common stock for nominal consideration. Both the January 2, 2014 and April 1, 2014 issuances of the shares and warrants were dilutive to the holders of the 2013 Warrants, 2013 Celgene Warrants, 2013 Convertible Notes, 2012 Warrants, 2012 Convertible Notes, and 2011 Warrants, and the anti-dilution provisions of each were simultaneously triggered. As of June 30, 2014, the exercise price of the 2011 Warrants was adjusted to $0.29 per share, and the number of shares issuable upon exercise of the 2011 Warrants was increased to 103,119,783 shares.
	The warrants contain provisions that require the modification of the exercise price and shares to be issued under certain circumstances, including in the event the Company completes subsequent equity financings at a price per share lower than the then-current warrant exercise price. In addition, the warrants contain a net cash settlement provision under which the warrant holders may require the Company to purchase the warrants in exchange for a cash payment following the announcement of specified events defined as Fundamental Transactions involving the Company (e.g., merger, sale of all or substantially all assets, tender offer, or share exchange). The net cash settlement provision requires use of the Black-Scholes model in calculating the cash payment value in the event of a Fundamental Transaction.
	The following tables summarize the calculated aggregate fair values for the liability-classified warrants as of the dates indicated along with the assumptions utilized in each calculation.
			Fair value as of June 30, 2014
			2011			2012				2013			2013			2013 and 2014 Interest
			Warrants			Warrants				Warrants			Celgene			Warrants
													Warrants
	Calculated aggregate value (in thousands)		$	4,468		$	13,839			$	20,199		$	8,191		$	303
	Exercise price per share of warrant		$	0.29		$	0.21			$	0.21		$	0.21		$	0.001
	Weighted-average equity volatility			110	%		110	%			110	%		110	%		110	%
	Weighted-average asset volatility			85	%		85	%			85	%		85	%		85	%
	Probability of Fundamental or Major Transaction			100	%		100	%			100	%		100	%		100	%
	Weighted-average risk-free interest rate			0.3	%		0.3	%			0.3	%		0.3	%		0.3	%
				Fair value as of December 31, 2013
				2011			2012				2013			2013			2013 Interest Warrants
				Warrants			Warrants				Warrants			Celgene Warrants
	Calculated aggregate value (in thousands)		$	720		$	3,430			$	5,139		$	2,083		$	53
	Exercise price per share of warrant		$	0.4		$	0.29			$	0.29		$	0.29		$	0.001
	Equity volatility			120	%		120	%			120	%		120	%		120	%
	Asset volatility			95	%		95	%			95	%		95	%		95	%
	Probability of Fundamental or Major Transaction			100	%		100	%			100	%		100	%		100	%
	Weighted-average risk-free interest rate			0.2	%		0.2	%			0.2	%		0.2	%		0.2	%
	The following table summarizes the calculated net cash settlement values for the liability-classified warrants as of the dates indicated along with the assumptions utilized in each calculation.
				Net cash settlement as of June 30, 2014
				2011			2012				2013			2013			2013 and
				Warrants			Warrants				Warrants			Celgene Warrants			2014
																	Interest Warrants
	Calculated aggregate value (in thousands) (1)		$	7,364		$	26,487			$	39,278		$	15,924			—
	Exercise price per share of warrant		$	0.29		$	0.21			$	0.21		$	0.21			—
	Closing price per share of warrant		$	0.19		$	0.19(2)			$	0.19(2)		$	0.19(2)			—
	Equity volatility (3)			100%			94%				94%			94%			—
	Expected term (years)			1.7			6.5				7.3			7.3			—
	Weighted-average risk-free interest rate			0.40%			1.80%				2.00%			2.00%			—
	Dividend yield			None			None				None			None			—
	-1	Represents the net cash settlement value of the warrant as of June 30, 2014, which value was calculated utilizing the Black-Scholes model specified in the warrant agreement.
	-2	Represents the five-day Company stock VWAP used to calculate the net cash settlement value as of June 30, 2014.
	-3	Represents the volatility assumption used to calculate the net cash settlement value as of June 30, 2014 based on the terms of the warrant agreement.
	During the six months ended June 30, 2013 and 2014, the Company recorded non-operating expense of $1.8 million and $35.3 million, respectively, due to a change in the estimated fair values of these warrants.  During the three months ended June 30, 2013 and 2014, the Company recorded non-operating expense of $1.9 million and $11.1 million, respectively, due to a change in the estimated fair values of these warrants.

Stockbased_Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2014
Stock-based Compensation [Abstract]	'
Stock-based Compensation	'
	-12	Stock-based Compensation
	The 2010 Stock Incentive and Option Plan (2010 Plan) became effective upon the closing of the Company’s initial public offering.  Under the 2010 Plan, stock awards may be granted to employees, directors, and consultants of the Company, in the form of restricted or unrestricted stock, stock appreciation rights, cash-based or performance share awards and stock options. The amounts and terms of options granted are determined by the Company’s compensation committee. The equity awards granted under the Plan generally vest over four years and have terms of up to ten years after the date of grant, and options are exercisable in cash or as otherwise determined by the board of directors.  The 2010 Plan allows for the transfer of forfeited shares from the 2004 Plan.  As of June 30, 2014, 156,143 shares of common stock were available for future grants under the 2010 Plan.
	Stock Options
	The following table summarizes stock option activity under the Plans:
			Number of		Weighted-		Weighted-average	Aggregate intrinsic
			shares		average		remaining	value (in thousands)
					exercise price		contractual term
							(in years)
	Outstanding at December 31, 2013		230,725		$	12.28	7.5
	Granted		—		$	—
	Exercised		—		$	—
	Forfeited		(768	)	$	22.45
	Outstanding at June 30, 2014		229,957		$	12.25	7	$	—
	Vested and expected to vest at June 30, 2014		223,062		$	12.42	7	$	—
	Exercisable at June 30, 2014		163,464		$	14.55	6.8	$	—
	Total stock-based compensation expense recognized for stock options to employees and non-employee directors for each of the three months ended June 30, 2013 and 2014 was $0.1 million.  Total stock-based compensation expense recognized for stock options to employees and non-employee directors for each of the six months ended June 30, 2013 and 2014 was $0.2 million.  As of June 30, 2014, there was $0.2 million of unrecognized compensation expense, net of forfeitures, related to non-vested employee and non-employee director stock options, which is expected to be recognized over a weighted-average period of 1.3 years.
	Restricted Stock
	The Company has issued restricted stock as compensation for the services of certain employees and other third parties.  The grant date fair value of restricted stock was based on the fair value of the common stock on the date of grant, and compensation expense is recognized ratably as the restrictions lapse.
	The following table summarizes restricted stock activity under the Plans:
			Number		Weighted-
			of shares		average
					grant date
					fair value
	Nonvested at December 31, 2013		54,721		$	7.59
	Granted		—		$	—
	Vested		(19,051	)	$	8.28
	Forfeited		(96	)	$	11.96
	Nonvested at June 30, 2014		35,574		$	7.19
	Total stock-based compensation expense for restricted stock was $36,000 and $51,000 for the three months ended June 30, 2013 and 2014, respectively.  Total stock-based compensation expense for restricted stock was $81,000 and $86,000 for the six months ended June 30, 2013 and 2014, respectively.  As of June 30, 2014, there was $0.2 million of unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 1.4 years.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	-13	Commitments and Contingencies
	Leases
	The Company leases office space and office equipment under operating leases, which expire at various times through February 2016.  Excluding the lease liability activity described in Note 7, rent expense under these operating leases was $9,000 and $46,000 for the three months ended June 30, 2013 and 2014, respectively, and $81,000 and $79,000 for the six months ended June 30, 2013 and 2014, respectively.
	The following table summarizes future minimum lease payments as of June 30, 2014 (in thousands):
	2014		$	530
	2015			1,079
	2016			276
	Total minimum lease payments (1)		$	1,885
	(1)The future minimum lease payments above do not include the impact of any potential sublease income discussed in Note 7 related to the Company’s lease liability.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	-14	Subsequent Events
	On July 1, 2014, the Company made interest payments to the holders of the 2012 Convertible Notes and the 2013 Convertible Notes by the issuance of 3,033,513 shares of common stock and warrants to purchase 1,327,026 shares of common stock for nominal consideration to satisfy approximately $0.8 million in interest obligations. The July 1, 2014 issuance of the shares and warrants was dilutive to the holders of the 2013 Warrants, 2013 Celgene Warrants, 2013 Convertible Notes, 2012 Warrants, 2012 Convertible Notes, and 2011 Warrants, and the anti-dilution provisions of each were simultaneously triggered. The conversion price of the 2012 and 2013 Convertible Notes was adjusted to $0.18 per share. The adjustments to the exercise price and the number of shares issuable upon exercise of the warrants were as follows:
			Shares	Weighted-
			exercisable	average
			as of July 1,	exercise
			2014	price
	2013 Warrants		308,066,691	$	0.18
	2013 Celgene Warrants		125,000,000	$	0.18
	2012 Warrants		220,180,579	$	0.18
	2011 Warrants		119,618,950	$	0.25

Summary_of_Accounting_Policies1

Summary of Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Summary of Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements, in accordance with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.  Actual results could differ from those estimates.  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
Recently Adopted Accounting Standards	'
	Recently Adopted Accounting Standards
	In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) – Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (ASU 2014-10).  ASU 2014-10 eliminates the concept of a development stage entity in its entirety from current accounting guidance. The new guidance eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of operations, stockholders’ equity and cash flows, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.  ASU 2014-10 is effective prospectively for public entities for annual reporting periods beginning after December 15, 2015, and interim periods within those annual periods however early adoption is permitted.  The Company evaluated and elected to adopt ASU 2014-10 as permitted, and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities in these financial statements.
Net Loss Per Share	'
	Net Loss Per Share
	Basic and diluted net loss attributable to common stockholders per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. For all periods presented, the outstanding shares of unvested restricted stock as well as the number of common shares issuable upon exercise of outstanding stock options and warrants and conversion of notes payable have been excluded from the calculation of diluted net loss attributable to common stockholders per share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and dilutive loss per share are the same.
	The following potentially dilutive securities have been excluded from the three and six month computations of diluted weighted-average shares outstanding as they would be anti-dilutive:
		June 30,
		2013		2014
	Shares underlying warrants outstanding		187,718,221		665,421,057
	Shares underlying options outstanding		232,046		229,957
	Unvested restricted stock		54,939		35,574
	Convertible notes payable		48,668,482		149,082,064
	The Company has determined that the net loss per share - basic and diluted for the three-month period ended March 31, 2014 was incorrectly stated in the Form 10-Q for the period ended March 31, 2014, resulting from an error in the calculation of weighted-average basic shares outstanding for the three-month period ended March 31, 2014. The Company determined that the error is not material to the March 31, 2014 financial statements. The net loss per share - basic and diluted for the three-month period ended March 31, 2014 was previously reported as $(1.91), while the corrected amount is $(2.55).

Summary_of_Accounting_Policies2

Summary of Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Accounting Policies [Abstract]	'
Schedule of antidilutive securities excluded from computation of earnings per share	'
	The following potentially dilutive securities have been excluded from the three and six month computations of diluted weighted-average shares outstanding as they would be anti-dilutive:
		June 30,
		2013		2014
	Shares underlying warrants outstanding		187,718,221		665,421,057
	Shares underlying options outstanding		232,046		229,957
	Unvested restricted stock		54,939		35,574
	Convertible notes payable		48,668,482		149,082,064

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2014
Supplemental Cash Flow Information [Abstract]	'
Supplemental cash flow information	'
	The following table contains additional supplemental cash flow information for the periods reported (in thousands).
		Six months ended
		June 30,
		2013		2014
	Supplemental disclosure of non-cash transactions:
	Fair value of embedded derivatives and derivatives issued with issuance of long-term debt	$	732	$	—
	Fair value of warrants issued with issuance of long-term debt		9,657		—
	Fair value of warrants issued pursuant to Celgene Collaboration and Option Agreement		3,390		—
	Conversion of warrant liability to common stock		15		—
	Conversion of 2012 and 2013 Convertible Notes to common stock, net		-		1,499
	Issuance of common stock and warrants for payment of interest		749		1,639

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Financial Instruments [Abstract]	'
Financial assets and liabilities measured at fair value on a recurring basis	'
	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liability measured at fair value on a recurring basis as of December 31, 2013 and June 30, 2014 (in thousands).
		Fair value measurement at reporting date using:
		Quoted prices in active markets for identical assets (Level 1)		Significant other observable		Significant unobservable inputs		Total
				inputs		(Level 3)
				(Level 2)
	At December 31, 2013
	Assets:
	Cash and cash equivalents	$	21,510	$	—	$	—	$	21,510
	Liabilities:
	Embedded derivative liability	$	—	$	—	$	226	$	226
	Warrant liability		—		—		11,425		11,425
		$	—	$	—	$	11,651	$	11,651
	At June 30, 2014:
	Assets:
	Cash and cash equivalents	$	10,124	$	—	$	—	$	10,124
	Liabilities:
	Embedded derivative liability	$	—	$	—	$	4,001	$	4,001
	Warrant liability		—		—		47,000		47,000
		$	—	$	—	$	51,001	$	51,001
Reconciliation of embedded derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3)	'
	A reconciliation of the embedded derivative liabilities is as follows (in thousands):
		2012 Notes		2013 Notes		Total
	Balance at December 31, 2013	$	101	$	125	$	226
	Change in fair value of derivative liability		1,687		2,088		3,775
	Balance at June 30, 2014	$	1,788	$	2,213	$	4,001
Reconciliation of warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3)	'
	A reconciliation of the warrant liability is as follows (in thousands):
		2011		2012		2013		2013		2013 and			Total
		Warrants		Warrants		Warrants		Celgene Warrants		2014
										Interest Warrants
	Balance at December 31, 2013	$	720	$	3,430	$	5,139	$	2,083	$	53		$	11,425
	Issuance of warrants		—		—		—		—		286			286
	Change in fair value of warrant liability		3,748		10,409		15,060		6,108		(36	)		35,289
	Balance at June 30, 2014	$	4,468	$	13,839	$	20,199	$	8,191	$	303		$	47,000

Accrued_expenses_Tables

Accrued expenses (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued expenses [Abstract]	'
Accrued expenses	'
	Accrued expenses consist of the following (in thousands):
		December 31,		June 30,
		2013		2014
	Accrued interest on convertible notes	$	843	$	781
	Accrued compensation and benefits		757		460
	Accrued consulting and professional fees		138		275
	Accrued research and development		535		199
	Other		93		92
	Total accrued expenses	$	2,366	$	1,807

Lease_liability_Tables

Lease liability (Tables)	6 Months Ended
	Jun. 30, 2014
Lease liability [Abstract]	'
Activity related to lease liability	'
	The following table summarizes the activity related to the lease liability for the six month period ended June 30, 2014 (in thousands).
		Warehouse			Office and manufacturing			Total
		space			space
	Balance at December 31, 2013	$	500		$	472		$	972
	Charges utilized		(128	)		(290	)		(418	)
	Additional charges to operations		27			277			304
	Balance at June 30, 2014		399			459			858
	Less current portion		246			429			675
	Total long-term lease liability at June 30, 2014	$	153		$	30		$	183

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt [Abstract]	'
Debt outstanding	'
	Total debt outstanding consists of the following (in thousands):
		December 31,			June 30,
		2013			2014
	Senior Secured 2012 Convertible Notes	$	14,634		$	14,505
	Embedded derivative liability-2012 Notes		101			1,788
	Senior Secured 2013 Convertible Notes		18,576			16,802
	Embedded derivative liability-2013 Notes		125			2,213
	Working Capital Note		1,382			—
	Unamortized debt discount		(7,866	)		(5,581	)
			26,952			29,727
	Less current portion		(1,329	)		—
	Total long-term debt and embedded derivative, net of debt discount	$	25,623		$	29,727

Embedded_Derivative_Conversion1

Embedded Derivative Conversion Options (Tables)	6 Months Ended
	Jun. 30, 2014
Embedded Derivative Conversion Options [Abstract]	'
Aggregate Fair Values of the Conversion Options	'
	The following table summarizes the calculated aggregate fair values using a risk-neutral framework within a Monte Carlo analysis of the Conversion Options as of the dates indicated along with assumptions utilized in each calculation.
			Embedded Derivative Liability
			Conversion Option-2012						Conversion Option-2013
			Notes						Notes
			31-Dec-13			June 30,			December 31,			June 30,
						2014			2013			2014
		$	101		$	1,788		$	125		$	2,213
	Calculated aggregate value (in thousands)
	Weighted-average equity volatility		120	%		110	%		120	%		110	%
	Weighted-average asset volatility		95	%		85	%		95	%		85	%
	Probability of a Major Transaction		100	%		100	%		100	%		100	%
	Weighted-average risk-free interest rate		0.2	%		0.3	%		0.2	%		0.3	%
	Dividend yield.	None			None			None			None

Warrants_Tables

Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Warrants [Abstract]	'
Outstanding warrants	'
	The following table summarizes outstanding warrants to purchase common stock:
			Shares Exercisable as of
			December 31,		June 30,		Weighted-average Exercise
			2013		2014		Price		Expiration
	Equity-classified warrants
	Issued to lenders and vendors		18,375		18,202	$	157.52		September 2014 through
									Sep-19
			18,375		18,202
	Liability-classified warrants
	2013 and 2014 Interest Warrants		1,057,944		2,356,848	$	0.001		July 2023 through April 2024
	2013 Warrants (1)		191,213,801		264,057,161	$	0.21		June 2018 through June 2023
	2013 Celgene Warrants (1)		77,586,207		107,142,857	$	0.21		June 2018 through June 2023
	2012 Warrants (1)		136,663,804		188,726,206	$	0.21		October 2014 through October 2022
	2011 Warrants (2)		74,761,830		103,119,783	$	0.29		Mar-16
			481,283,586		665,402,855
	Total		481,301,961		665,421,057
	(1)As of December 31, 2013 the 2013 Warrants, 2013 Celgene Warrants and 2012 Warrants had an exercise price of $0.29 per share.
	(2)As of December 31, 2013 the 2011 Warrants had an exercise price of $0.40 per share.
Aggregate fair values for the liability-classified warrants	'
	The following tables summarize the calculated aggregate fair values for the liability-classified warrants as of the dates indicated along with the assumptions utilized in each calculation.
			Fair value as of June 30, 2014
			2011			2012				2013			2013			2013 and 2014 Interest
			Warrants			Warrants				Warrants			Celgene			Warrants
													Warrants
	Calculated aggregate value (in thousands)		$	4,468		$	13,839			$	20,199		$	8,191		$	303
	Exercise price per share of warrant		$	0.29		$	0.21			$	0.21		$	0.21		$	0.001
	Weighted-average equity volatility			110	%		110	%			110	%		110	%		110	%
	Weighted-average asset volatility			85	%		85	%			85	%		85	%		85	%
	Probability of Fundamental or Major Transaction			100	%		100	%			100	%		100	%		100	%
	Weighted-average risk-free interest rate			0.3	%		0.3	%			0.3	%		0.3	%		0.3	%
				Fair value as of December 31, 2013
				2011			2012				2013			2013			2013 Interest Warrants
				Warrants			Warrants				Warrants			Celgene Warrants
	Calculated aggregate value (in thousands)		$	720		$	3,430			$	5,139		$	2,083		$	53
	Exercise price per share of warrant		$	0.4		$	0.29			$	0.29		$	0.29		$	0.001
	Equity volatility			120	%		120	%			120	%		120	%		120	%
	Asset volatility			95	%		95	%			95	%		95	%		95	%
	Probability of Fundamental or Major Transaction			100	%		100	%			100	%		100	%		100	%
	Weighted-average risk-free interest rate			0.2	%		0.2	%			0.2	%		0.2	%		0.2	%
Net cash settlement values for the liability-classified warrants	'
	The following table summarizes the calculated net cash settlement values for the liability-classified warrants as of the dates indicated along with the assumptions utilized in each calculation.
				Net cash settlement as of June 30, 2014
				2011			2012				2013			2013			2013 and
				Warrants			Warrants				Warrants			Celgene Warrants			2014
																	Interest Warrants
	Calculated aggregate value (in thousands) (1)		$	7,364		$	26,487			$	39,278		$	15,924			—
	Exercise price per share of warrant		$	0.29		$	0.21			$	0.21		$	0.21			—
	Closing price per share of warrant		$	0.19		$	0.19(2)			$	0.19(2)		$	0.19(2)			—
	Equity volatility (3)			100%			94%				94%			94%			—
	Expected term (years)			1.7			6.5				7.3			7.3			—
	Weighted-average risk-free interest rate			0.40%			1.80%				2.00%			2.00%			—
	Dividend yield			None			None				None			None			—
	-1	Represents the net cash settlement value of the warrant as of June 30, 2014, which value was calculated utilizing the Black-Scholes model specified in the warrant agreement.
	-2	Represents the five-day Company stock VWAP used to calculate the net cash settlement value as of June 30, 2014.
	-3	Represents the volatility assumption used to calculate the net cash settlement value as of June 30, 2014 based on the terms of the warrant agreement.

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Stock-based Compensation [Abstract]	'
Stock option activity	'
	The following table summarizes stock option activity under the Plans:
		Number of		Weighted-		Weighted-average	Aggregate intrinsic
		shares		average		remaining	value (in thousands)
				exercise price		contractual term
						(in years)
	Outstanding at December 31, 2013	230,725		$	12.28	7.5
	Granted	—		$	—
	Exercised	—		$	—
	Forfeited	(768	)	$	22.45
	Outstanding at June 30, 2014	229,957		$	12.25	7	$	—
	Vested and expected to vest at June 30, 2014	223,062		$	12.42	7	$	—
	Exercisable at June 30, 2014	163,464		$	14.55	6.8	$	—
Restricted stock activity	'
	The following table summarizes restricted stock activity under the Plans:
		Number		Weighted-
		of shares		average
				grant date
				fair value
	Nonvested at December 31, 2013	54,721		$	7.59
	Granted	—		$	—
	Vested	(19,051	)	$	8.28
	Forfeited	(96	)	$	11.96
	Nonvested at June 30, 2014	35,574		$	7.19

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies [Abstract]	'
Future minimum lease payments	'
	The following table summarizes future minimum lease payments as of June 30, 2014 (in thousands):
	2014	$	530
	2015		1,079
	2016		276
	Total minimum lease payments (1)	$	1,885
	(1)The future minimum lease payments above do not include the impact of any potential sublease income discussed in Note 7 related to the Company’s lease liability.

Subsequent_Events_Tables

Subsequent Events (Tables)	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Adjustments to exercise price and number of shares issuable upon exercise of Warrants	'
	The adjustments to the exercise price and the number of shares issuable upon exercise of the warrants were as follows:
		Shares	Weighted-
		exercisable	average
		as of July 1,	exercise
		2014	price
	2013 Warrants	308,066,691	$	0.18
	2013 Celgene Warrants	125,000,000	$	0.18
	2012 Warrants	220,180,579	$	0.18
	2011 Warrants	119,618,950	$	0.25

Managements_Plans_to_Continue_1

Management's Plans to Continue as a Going Concern (Details) (USD $)	132 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Management's Plans to Continue as a Going Concern [Abstract]	'	'
Deficit accumulated during the development stage	($318,213,000)	($266,100,000)
Cumulative accretion on redeemable convertible preferred stock	$48,400,000	'

Summary_of_Accounting_Policies3

Summary of Accounting Policies (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Shares underlying warrants outstanding [Member]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	665,421,057	187,718,221	665,421,057	187,718,221
Shares underlying options outstanding [Member]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	229,957	232,046	229,957	232,046
Unvested restricted stock [Member]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	35,574	54,939	35,574	54,939
Convertible notes payable [Member]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	149,082,064	48,668,482	149,082,064	48,668,482

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Supplemental disclosure of non-cash transactions [Abstract]	'	'
Fair value of embedded derivatives and derivatives issued with issuance of long-term debt	$0	$732
Fair value of warrants issued with issuance of long term debt	0	9,657
Fair value of warrants issued pursuant to Celgene Collaboration and Option Agreement	0	3,390
Conversion of warrant liability to common stock	0	15
Conversion of 2012 and 2013 Convertible Notes to common stock, net	1,499	0
Issuance of common stock and warrants for payment of interest	$1,639	$749

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Assets [Abstract]	'	'
Cash and cash equivalents	$10,124	$21,510
Liabilities [Abstract]	'	'
Total fair value of liabilities	51,001	11,651
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	11,425	'
Issuance of warrants	286	'
Change in fair value	35,289	'
Balance	47,000	'
Common stock value (in dollars per share)	$0.08	$0.02
2011 Warrants [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	720	'
Issuance of warrants	0	'
Change in fair value	3,748	'
Balance	4,468	'
2012 Warrants [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	3,430	'
Issuance of warrants	0	'
Change in fair value	10,409	'
Balance	13,839	'
2013 Warrants [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	5,139	'
Issuance of warrants	0	'
Change in fair value	15,060	'
Balance	20,199	'
2013 Celgene Warrants [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	2,083	'
Issuance of warrants	0	'
Change in fair value	6,108	'
Balance	8,191	'
2013 Interest Warrants [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	53	'
Issuance of warrants	286	'
Change in fair value	-36	'
Balance	303	'
2012 Notes [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	101	'
Change in fair value	1,687	'
Balance	1,788	'
2013 Notes [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	125	'
Change in fair value	2,088	'
Balance	2,213	'
Conversion Option [Member]	'	'
Reconciliation of embedded derivative warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) [Abstract]	'	'
Balance	226	'
Change in fair value	3,775	'
Balance	4,001	'
Embedded Derivative liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	4,001	226
Warrant liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	47,000	11,425
Quoted prices in active markets for identical assets (Level 1) [Member]	'	'
Assets [Abstract]	'	'
Cash and cash equivalents	10,124	21,510
Liabilities [Abstract]	'	'
Total fair value of liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Embedded Derivative liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Warrant liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	0	0
Significant other observable inputs (Level 2) [Member]	'	'
Assets [Abstract]	'	'
Cash and cash equivalents	0	0
Liabilities [Abstract]	'	'
Total fair value of liabilities	0	0
Significant other observable inputs (Level 2) [Member] | Embedded Derivative liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	0	0
Significant other observable inputs (Level 2) [Member] | Warrant liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	0	0
Significant unobservable inputs (Level 3) [Member]	'	'
Assets [Abstract]	'	'
Cash and cash equivalents	0	0
Liabilities [Abstract]	'	'
Total fair value of liabilities	51,001	11,651
Significant unobservable inputs (Level 3) [Member] | Embedded Derivative liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	4,001	226
Significant unobservable inputs (Level 3) [Member] | Warrant liability [Member]	'	'
Liabilities [Abstract]	'	'
Total fair value of liabilities	$47,000	$11,425

Accrued_expenses_Details

Accrued expenses (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued expenses [Abstract]	'	'
Accrued interest on convertible notes	$781	$843
Accrued compensation and benefits	460	757
Accrued consulting and professional fees	275	138
Accrued research and development	199	535
Other	92	93
Total accrued expenses	$1,807	$2,366

Lease_liability_Details

Lease liability (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Activity related to lease liability [Abstract]	'	'
Balance, beginning of period	$972	'
Charges utilized	-418	'
Additional charges to operations	304	'
Balance, end of period	858	'
Less current portion	675	665
Total long-term lease liability	183	307
Warehouse space [Member]	'	'
Capital Leased Assets [Line Items]	'	'
Lease term	'5 years	'
Activity related to lease liability [Abstract]	'	'
Balance, beginning of period	500	'
Charges utilized	-128	'
Additional charges to operations	27	'
Balance, end of period	399	'
Less current portion	246	'
Total long-term lease liability	153	'
Office and manufacturing space [Member]	'	'
Activity related to lease liability [Abstract]	'	'
Balance, beginning of period	472	'
Charges utilized	-290	'
Additional charges to operations	277	'
Balance, end of period	459	'
Less current portion	429	'
Total long-term lease liability	$30	'

Debt_Details

Debt (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Oct. 02, 2012

Jun. 30, 2014

Dec. 31, 2013

Oct. 02, 2012

Oct. 02, 2012

Jun. 30, 2014

Dec. 31, 2013

Jun. 28, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Senior Secured 2012 Convertible Notes [Member]

Senior Secured 2012 Convertible Notes [Member]

Senior Secured 2012 Convertible Notes [Member]

Senior Secured 2012 Convertible Notes [Member]

Senior Secured 2012 Convertible Notes [Member]

Embedded derivative liability-2012 Notes [Member]

Embedded derivative liability-2012 Notes [Member]

Senior Secured 2013 Convertible Notes [Member]

Senior Secured 2013 Convertible Notes [Member]

Senior Secured 2013 Convertible Notes [Member]

Senior Secured 2013 Convertible Notes [Member]

Embedded derivative liability-2013 Notes [Member]

Embedded derivative liability-2013 Notes [Member]

Working Capital Note [Member]

Working Capital Note [Member]

Senior Secured 2012 And 2013 Convertible Notes [Member]

Senior Secured 2012 And 2013 Convertible Notes And Working Capital Note [Member]

Senior Secured 2012 And 2013 Convertible Notes And Working Capital Note [Member]

Senior Secured 2012 Convertible Notes And Working Capital Note [Member]

Senior Secured 2012 Convertible Notes And Working Capital Note [Member]

Warrants issued for five years [Member]

Warrants issued for ten years [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total debt

$29,727,000

'

$29,727,000

'

$26,952,000

$15,005,251

$14,505,000

$14,634,000

'

'

$1,788,000

$101,000

$18,576,000

$16,802,000

$16,802,000

$18,576,000

$2,213,000

$125,000

$0

$1,382,000

'

'

'

'

'

Convertible notes to purchase common stock (in shares)

'

'

'

'

'

1,118,722

'

'

'

'

'

'

26,921,741

'

'

'

'

'

'

'

'

'

'

'

'

Exercise period of convertible notes

'

'

'

'

'

'2 years

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common stock (in shares)

665,421,057

'

665,421,057

'

481,301,961

'

69,072,625

'

16,672,145

33,344,293

'

'

53,843,479

80,009,439

80,009,439

'

'

'

'

'

'

'

'

'

'

Exercise period of warrants

'

'

'

'

'

'

'

'

'5 years

'10 years

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per share)

'

'

'

'

'

$0.75

'

'

'

'

'

'

$0.69

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price (in dollars per share)

'

'

'

'

'

'

$0.21

'

'

'

'

'

$0.69

$0.21

$0.21

'

'

'

'

'

'

'

'

'

'

Debt instrument, maturity date

'

'

'

'

'

2-Oct-15

'

'

'

'

'

'

30-Jun-16

'

'

'

'

'

'

'

'

'

'

'

'

Debt interest rate (in hundredths)

'

'

'

'

'

10.00%

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock shares can be convert by convertible notes (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

26,921,740

'

'

'

'

'

'

'

'

'

'

'

'

Number of trading days considered for volume weighted average price of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

'

Interest expense

1,881,000

1,830,000

3,845,000

3,257,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,600,000

800,000

1,600,000

'

'

Amortization of deferred financing costs

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

700,000

'

'

'

'

'

'

'

'

700,000

1,500,000

Issuance of common stock to convertible noteholders (in shares)

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

Debt conversion original debt amount

'

'

'

'

'

'

$638,480

'

'

'

'

'

'

'

$8,097,256

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for payment of interest (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,292,552

'

'

'

'

Issuance of warrants for payment of interest (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,298,904

'

'

'

'

Debt_Debt_Outstanding_Details

Debt, Debt Outstanding (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Oct. 02, 2012

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 28, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Senior Secured 2012 Convertible Notes [Member]

Senior Secured 2012 Convertible Notes [Member]

Senior Secured 2012 Convertible Notes [Member]

Embedded derivative liability-2012 Notes [Member]

Embedded derivative liability-2012 Notes [Member]

Senior Secured 2013 Convertible Notes [Member]

Senior Secured 2013 Convertible Notes [Member]

Senior Secured 2013 Convertible Notes [Member]

Embedded derivative liability-2013 Notes [Member]

Embedded derivative liability-2013 Notes [Member]

Working Capital Note [Member]

Working Capital Note [Member]

Total debt outstanding [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total debt

$29,727,000

$26,952,000

$14,505,000

$14,634,000

$15,005,251

$1,788,000

$101,000

$16,802,000

$18,576,000

$18,576,000

$2,213,000

$125,000

$0

$1,382,000

Unamortized debt discount

-5,581,000

-7,866,000

'

'

'

'

'

'

'

'

'

'

'

'

Less current portion

0

-1,329,000

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt and embedded derivative, net

$29,727,000

$25,623,000

'

'

'

'

'

'

'

'

'

'

'

'

Capital_Structure_Details

Capital Structure (Details)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Capital Structure [Abstract]	'	'
Common stock, shares authorized (in shares)	10,000,000,000	750,000,000
Common stock, voting rights	'Each holder of common stock is entitled to one vote for each share held.	'
Subsidiary, Sale of Stock [Line Items]	'	'
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
2013 Agreements Celgene [Member]	'	'
Subsidiary, Sale of Stock [Line Items]	'	'
Maximum number of days specified in the agreement by when a registration statement needs to be filed	'30 days	'
2012 Financing [Member]	'	'
Subsidiary, Sale of Stock [Line Items]	'	'
Maximum number of days specified in the agreement by when a registration statement needs to be filed	'30 days	'

Embedded_Derivative_Conversion2

Embedded Derivative Conversion Options (Details) (Derivative Liability [Member], USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Conversion Option - 2012 Notes [Member]	'	'
Summary of aggregate fair values along with assumptions utilized [Abstract]	'	'
Calculated aggregate value	$1,788	$101
Weighted average equity volatility (in hundredths)	110.00%	120.00%
Weighted average asset volatility (in hundredths)	85.00%	95.00%
Probability of a Major Transaction (in hundredths)	100.00%	100.00%
Weighted average risk-free interest rate (in hundredths)	0.30%	0.20%
Dividend yield (in hundredths)	'	'
Conversion Option - 2013 Notes [Member]	'	'
Summary of aggregate fair values along with assumptions utilized [Abstract]	'	'
Calculated aggregate value	$2,213	$125
Weighted average equity volatility (in hundredths)	110.00%	120.00%
Weighted average asset volatility (in hundredths)	85.00%	95.00%
Probability of a Major Transaction (in hundredths)	100.00%	100.00%
Weighted average risk-free interest rate (in hundredths)	0.30%	0.20%
Dividend yield (in hundredths)	'	'

Warrants_Details

Warrants (Details) (USD $)

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Oct. 02, 2012

Jun. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Jun. 28, 2013

Jun. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Mar. 31, 2011

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

2011 Warrants [Member]

2011 Warrants [Member]

2012 Warrants [Member]

2012 Warrants [Member]

2012 Warrants [Member]

2013 Warrants [Member]

2013 Warrants [Member]

2013 Warrants [Member]

2013 Warrants [Member]

2013 Celgene Warrants [Member]

2013 Celgene Warrants [Member]

2013 Celgene Warrants [Member]

2013 Interest Warrants [Member]

2013 and 2014 Interest Warrants [Member]

Equity classified warrants [Member]

Equity classified warrants [Member]

Equity classified warrants [Member]

Equity classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Liability classified warrants [Member]

Warrants Issued To Vendors Expired From September 2014 Through September 2019 [Member]

Warrants Issued To Vendors Expired From September 2014 Through September 2019 [Member]

Interest Warrants Issued To Lenders From July 2023 Through April 2024 [Member]

Interest Warrants Issued To Lenders From July 2023 Through April 2024 [Member]

Warrants Issued to lenders from June 2018 through June 2023 [Member]

Warrants Issued to lenders from June 2018 through June 2023 [Member]

Celgene Warrants Issued to lenders from June 2018 through June 2023 [Member]

Celgene Warrants Issued to lenders from June 2018 through June 2023 [Member]

Warrants issued pursuant to October 2012 debt financing, expired from October 2014 through October 2022 [Member]

Warrants issued pursuant to October 2012 debt financing, expired from October 2014 through October 2022 [Member]

Warrants issued pursuant to March 2011 equity financing, expired in March 2016 [Member]

Warrants issued pursuant to March 2011 equity financing, expired in March 2016 [Member]

Warrants issued pursuant to March 2011 equity financing, expired in March 2016 [Member]

2012 Warrants [Member]

2013 Celgene Warrants [Member]

2013 Celgene Warrants [Member]

Cashless Warrants [Member]

Five-Year Warrants [Member]

Ten-Year Warrants [Member]

Outstanding warrants to purchase common stock [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Exercisable (in shares)

665,421,057

481,301,961

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,202

18,375

18,202

18,375

665,402,855

'

665,402,855

'

481,283,586

2,356,848

1,057,944

264,057,161

[1]

191,213,801

[1]

107,142,857

[1]

77,586,207

[1]

188,726,206

[1]

136,663,804

[1]

103,119,783

[2]

74,761,830

[2]

1,046,102

7,425,743

'

14,851,485

Exercise Price (in dollars per share)

'

'

$0.29

$0.40

$0.21

$0.29

$0.75

$0.21

$0.29

'

$0.69

$0.21

$0.29

'

'

$0

'

'

$157.52

'

'

'

'

'

'

$0.00

'

$0.21

[1]

'

$0.21

[1]

'

$0.21

[1]

'

$0.29

[2]

'

$28.80

'

$1.01

$1.01

Expiration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'September 2014 through September 2019

'

'

'

'

'

'

'July 2023 through April 2024

'

'June 2018 through June 2023

[1]

'

'June 2018 through June 2023

[1]

'

'October 2014 through October 2022

[1]

'

'March 1, 2016

[2]

'

'

'

'

'

Proceeds from exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15,000,000

Warrants expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'10 years

Fair value [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Calculated aggregate value

'

'

4,468,000

720,000

13,839,000

3,430,000

'

20,199,000

'

5,139,000

'

8,191,000

'

2,083,000

53,000

303,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share of warrant (in dollars per share)

'

'

$0.29

$0.40

$0.21

$0.29

'

$0.21

'

$0.29

'

$0.21

'

$0.29

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average equity volatility (in hundredths)

'

'

110.00%

120.00%

110.00%

120.00%

'

110.00%

120.00%

'

'

110.00%

120.00%

'

120.00%

110.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average asset volatility (in hundredths)

'

'

85.00%

95.00%

85.00%

95.00%

'

85.00%

95.00%

'

'

85.00%

95.00%

'

95.00%

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Probability of Fundamental or Major Transaction (in hundredths)

'

'

100.00%

100.00%

100.00%

100.00%

'

100.00%

100.00%

'

'

100.00%

100.00%

'

100.00%

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average risk-free interest rate (in hundredths)

'

'

0.30%

0.20%

0.30%

0.20%

'

0.30%

0.20%

'

'

0.30%

0.20%

'

0.20%

0.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net cash settlement value [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Calculated aggregate value

'

'

7,364,000

[3]

'

26,487,000

[3]

'

'

39,278,000

[3]

'

'

'

15,924,000

[3]

'

'

'

0

[3]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share of warrant (in dollars per share)

'

'

$0.29

$0.40

$0.21

$0.29

$0.75

$0.21

$0.29

'

$0.69

$0.21

$0.29

'

'

$0

'

'

$157.52

'

'

'

'

'

'

$0.00

'

$0.21

[1]

'

$0.21

[1]

'

$0.21

[1]

'

$0.29

[2]

'

$28.80

'

$1.01

$1.01

Closing price per share of warrant (in dollars per share)

'

'

$0.19

'

$0.19

[4]

'

'

$0.19

[4]

'

'

'

$0.19

[4]

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity volatility (in hundredths)

'

'

100.00%

[5]

'

94.00%

[5]

'

'

94.00%

[5]

'

'

'

94.00%

[5]

'

'

'

0.00%

[5]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term (years)

'

'

'1 year 8 months 12 days

'

'6 years 6 months

'

'

'7 years 3 months 18 days

'

'

'

'7 years 3 months 18 days

'

'

'

'0 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average risk-free interest rate (in hundredths)

'

'

0.40%

'

1.80%

'

'

2.00%

'

'

'

2.00%

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of volume weighted average price used to calculate net cash settlement value

'5 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-operating income (expense)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$11,100,000

$1,900,000

($35,300,000)

($1,800,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

As of December 31, 2013 the 2013 Warrants, 2013 Celgene Warrants and 2012 Warrants had an exercise price of $0.29 per share.

[2]

As of December 31, 2013 the 2011 Warrants had an exercise price of $0.40 per share.

[3]

(1) Represents the net cash settlement value of the warrant as of June 30, 2014, which value was calculated utilizing the Black-Scholes model specified in the warrant agreement.

[4]

(2) Represents the five-day Company stock VWAP used to calculate the net cash settlement value as of June 30, 2014.

[5]

(3) Represents the volatility assumption used to calculate the net cash settlement value as of June 30, 2014 based on the terms of the warrant agreement.

Stockbased_Compensation_Detail

Stock-based Compensation (Details) (USD $)

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Dec. 31, 2003

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

2004 Stock Option Plan [Member]

2004 Stock Option Plan [Member]

2010 Stock Option Plan [Member]

2010 Stock Option Plan [Member]

2010 Stock Option Plan [Member]

Employee And Non Employee Director [Member]

Employee And Non Employee Director [Member]

Employee And Non Employee Director [Member]

Employee And Non Employee Director [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity awards granted under plan vesting period

'

'

'

'

'

'

'

'

'

'

'4 years

'10 years

'

'4 years

'10 years

Number of shares available for future grants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

156,143

'

'

Number of shares [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in shares)

230,725

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in shares)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in shares)

-768

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in shares)

229,957

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at June 30, 2014 (in shares)

223,062

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at June 30, 2014 (in shares)

163,464

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average exercise price [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in dollars per share)

$12.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars per share)

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in dollars per share)

$22.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in dollars per share)

$12.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at June 30, 2014 (in dollars per share)

$12.42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at June 30, 2014 (in dollars per share)

$14.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average remaining contractual term [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding

'7 years

'7 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding

'7 years

'7 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at June 30, 2014

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at June 30, 2014

'6 years 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at June 30, 2014

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at June 30, 2014

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

200,000

100,000

200,000

200,000

51,000

36,000

86,000

81,000

'

'

'

'

'

Unrecognized compensation expense

'

'

200,000

'

200,000

'

'

'

'

'

'

'

'

'

'

Weighted average period for recognizing compensation expense

'

'

'

'

'1 year 3 months 18 days

'

'

'

'1 year 4 months 24 days

'

'

'

'

'

'

Number of shares [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonvested (in shares)

'

'

'

'

'

'

'

'

54,721

'

'

'

'

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Vested (in shares)

'

'

'

'

'

'

'

'

-19,051

'

'

'

'

'

'

Forfeited (in shares)

'

'

'

'

'

'

'

'

-96

'

'

'

'

'

'

Nonvested (in shares)

'

'

'

'

'

'

35,574

'

35,574

'

'

'

'

'

'

Weighted-average grant date fair value [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonvested (in dollars per share)

'

'

'

'

'

'

'

'

$7.59

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

Vested (in dollars per share)

'

'

'

'

'

'

'

'

$8.28

'

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

'

'

'

'

'

$11.96

'

'

'

'

'

'

Nonvested (in dollars per share)

'

'

'

'

'

'

$7.19

'

$7.19

'

'

'

'

'

'

Unrecognized compensation expense related to restricted stock awards

'

'

'

'

'

'

$200,000

'

$200,000

'

'

'

'

'

'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013
Commitments and Contingencies [Abstract]	'		'	'		'
Rent expenses under operating lease	$46,000		$9,000	$79,000		$81,000
Summarizes future minimum lease payments [Abstract]	'		'	'		'
2014	530,000		'	530,000		'
2015	1,079,000		'	1,079,000		'
2016	276,000		'	276,000		'
Total minimum lease payments	$1,885,000	[1]	'	$1,885,000	[1]	'
[1]	The future minimum lease payments above do not include the impact of any potential sublease income discussed in Note 7 related to the Company's lease liability.

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	6 Months Ended							0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jul. 01, 2014	Jul. 01, 2014	Jul. 01, 2014	Jul. 01, 2014	Jul. 01, 2014	Jul. 01, 2014
				2013 Warrants [Member]	2013 Celgene Warrants [Member]	2012 Warrants [Member]	2011 Warrants [Member]	Subsequent Event [Member]	Subsequent Event [Member]
								2012 and 2013 Convertible Notes [Member]	2012 and 2013 Convertible Notes [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'
Number of common stock issued for conversion of convertible notes (in shares)	'	'	'	'	'	'	'	3,033,513	'
Number of common stock purchases for nominal consideration (in shares)	'	'	'	'	'	'	'	1,327,026	'
Convertible notes value, converted into common stock	$1,499	$0	'	'	'	'	'	$800	'
Conversion price of convertible notes (in dollars per share)	'	'	'	'	'	'	'	'	$0.18
Warrants to purchase common stock (in shares)	665,421,057	'	481,301,961	308,066,691	125,000,000	220,180,579	119,618,950	'	'
Exercise price of warrants (in dollars per share)	'	'	'	$0.18	$0.18	$0.18	$0.25	'	'